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Short QT syndrome (SQTS) is an inherited, rare, potentially
lethal disease characterized by ventricular repolarization
alterations, predisposing individuals to atrial ﬁbrillation
(AF), syncope, and high incidence of sudden cardiac death
(SCD), often during the ﬁrst years of life.1,2 SQTS was ﬁrst
described in a family in which some members showed an
abnormally short QT interval and 1 of them suffered from
AF. An additional patient had a short QT interval,
recurrent ventricular arrhythmias, and, ultimately, SCD.3
The diagnosis of SQTS requires a short QT interval on the
resting electrocardiogram (ECG), although its importance
remains ambiguous. There is debate over what constitutes
a short QT interval and the lower limit of normal changes
with age.4 Recently the ﬁrst diagnostic criteria for SQTS
have been published,5 although several diagnostic limi-
tations have been discussed.6 Recently a multicenter
pediatric cohort of 25 patients with SQTS has been
described.7
Genetic publications have reported gain-of-function patho-
genic mutations mainly in 3 different potassium channels
(KCNQ1, KCNH2, and KCNJ2).8–10 In 2011, a pathogenicKEYWORDS Arrhythmia; Genetics; Pediatrics; Sudden death
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).variant in CACNA2D1 was reported to be associated with
SQTS.11 In addition, pathogenic mutations in 2 L-type calcium
channels (CACNA1C andCACNB2B)12 have also been reported
in a speciﬁc phenotype of Brugada syndromewith shortenedQT
interval. At present, robust genotype–phenotype correlation data
are not yet available for SQTS, and thus management must rely
on clinical ﬁndings.13
AF is deﬁned as an erratic activation of the atria, causing
an irregular ventricular response.14 AF is the most common
distressing cardiac arrhythmia encountered in clinical prac-
tice in the adult population.15 In the pediatric population AF
is an extremely rare entity.16 Genetic predisposition contrib-
utes to the development of AF.17 To date, more than 15
genes have been described.18 AF has been associated with
long QT syndrome19–22 and with SQTS.23–26
In 2005, a case showing AF in utero with concomitant
bradycardia, short QT interval, and a structurally normal
heart was described. Genetic analysis revealed a de novo
point mutation (p.V141M) in the KCNQ1 gene.27 The
KCNQ1 gene codiﬁes KVLQT1 (Kv7.1), a voltage-
activated potassium channel alpha-subunit expressed in
various cell types, including cardiac myocytes. In the
publication by Villafane et al7 3 of those 25 patients
had SQTS and AF. Of those, 1 has the previously reported p.
V141M_KCNQ1mutation. Recently, Villafane et al28 have also
reported 2 neonates with AF, structurally normal hearts, and a
slow ventricular response rate occurring in association with
SQTS. In both individuals, the p.V141M mutation in the
KCNQ1 gene was identiﬁed. Here we report the clinical
follow-up of 3 new unrelated babies, all them diagnosed in
utero with the same clinical diagnosis of AF with concomitant
bradycardia and short QT interval.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.02.005
KEY TEACHING POINTS
 The mutation p.V141M_KCNQ1 is a highly
pathogenic variant leading to ventricular dilatation
and heart failure development.
 Genetic analysis should be performed in patients
with similar clinical ﬁndings owing to high risk of
sudden cardiac death.
 Patient follow-up should be performed because of
persistent atrial ﬁbrillation and short QT intervals
with mild to severe forms of ventricular dilatation
and high risk of sudden cardiac death.
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Clinical analysis
Individuals were clinically evaluated in pediatric arrhyth-
mology services of university hospitals following the same
diagnostic techniques for fetal ultrasound, pediatric ECG,
and echocardiography. All individuals are white.Genetic analysis
Informed consent for genetic analysis was obtained from all
patients or their legal representatives, in accordance with
local institutional review board guidelines of Hospital Josep
Trueta (Girona, Spain) and Universitat of Girona (Girona,
Spain). The study protocol conforms to the Declaration of
Helsinki.
Blood samples were obtained from all 3 patients (3 mL)
and from their parents (10 mL). Mutational analysis genomic
DNA was isolated from peripheral blood leukocytes using a
commercial kit (Gentra System; Puregene). Genetic screening
was performed by direct sequencing of the exons and exon–
intron boundaries. The exons were ampliﬁed and analyzed by
direct sequencing. Polymerase chain reaction products were
puriﬁed with a commercial reagent (ExoSAP-IT, USB) and
were directly sequenced from both directions using Genetic
Analyzer 3130XL (Applied Biosystems, Life Technologies).
Genetic analysis was performed in the 3 main SQTS-
related genes published to date. Therefore, we examine
the contribution of KCNQ1 (NM000218.2), KCNH2
(NM000238.2), and KCNJ2 (NM000891.2) in all 3 unrelated
cases (UCSC Genome bioinformatics/NCBI Mendelian
Inheritance in Man). The previously reported variants were
named with Human Gene Mutation Database accession
codes. Data regarding genetic variants identiﬁed were
consulted in available online databases such as the 1000
Genomes project (http://browser.1000genomes.org/) and
Exome Sequencing Project (http://evs.gs.washington.edu/
EVS/) to study their frequency in the general population.
Alignment of species was consulted in the UniProt database
(http://www.uniprot.org/). The potential pathogenic role
of missense genetic variants was consulted in the CON-
DEL (CONsensus DELeteriousness score of missense SNVs)
database (http://bg.upf.edu/condel/home), Mutation Taster(www.mutationtaster.org), and PROVEAN (Protein Variation
Effect Analyzer) (http://provean.jcvi.org/index.php).Results
Clinical ﬁndings
Patient 1 presented with asymptomatic fetal arrhythmia at 24
gestational weeks. Cardiac rhythm was assessed using
M-mode and ascending aorta–superior vena cava Doppler
recordings suggesting AF. The baby was delivered at 37
weeks gestation. After birth, this female newborn was
hemodynamically stable, but an irregular rhythm was
auscultated. The 12-lead ECG showed AF, narrow QRS
response at 80–120 bpm, and short QTc interval between
270 and 310 ms. Chest radiograph, echocardiography, and
electrolyte levels were normal. Electric cardioversion was
attempted with no success. The patient was put under daily
aspirin treatment. She remained asymptomatic until the age
of 2.5 years when she complained of dizziness. A 24-hour
ECG Holter test showed symptomatic 5-second pauses;
therefore, a pacemaker was implanted using an epicardial
right ventricle (RV) lead. She did well during the ﬁrst 12
months after implant, but she progressively developed
dilated cardiomyopathy refractory to diuretic treatment
(furosemide, spirinolactone) plus digoxin and carvedilol;
thus, resynchronization was attempted by implanting an
epicardial left ventricle (LV) lead. Unfortunately, 1 week
later the RV lead failed and no further surgical interventions
were attempted; therefore, she was left under epicardial LV
stimulation. Mildly improved LV function was observed so
she was kept under diuretic, digoxin, and carvedilol and
followed closely by her cardiologist. At age 8, progressive
worsening of the LV function was observed and while she
was being evaluated for an eventual heart transplant, she died
suddenly (no available recordings). Clinical assessment of
parents showed no cardiac alterations.
Patient 2 presented with persistent fetal bradycardia at
26.3 gestational weeks. As congenital AV block was
suspected, betamethasone was started. Maternal autoimmune
screening was negative. At 28.4 weeks the mother was
hospitalized for preterm labor and a terbutaline pump was
started. The heart rate varied from 70 to 120 bpm. At 35.5
weeks the fetus had a heart rate of 70 bpm, no signs of
hydrops, and only a slightly dilated inferior vena cava. At 37
gestational weeks the infant male was delivered by caesarean
section. Postdelivery, the ECG showed short a QTc interval
(290 ms) and AF (Figure 1). Electric cardioversion was
unsuccessful even after quinidine load. Owing to persistent
bradycardia, an epicardial DDD device was placed initially;
however, because of poor atrial thresholds and the presence
of AF, the device was programmed VVIR and has remained
so since then. At 8 years of age the child is asymptomatic
with mild left ventricular dilatation but normal LV function.
He has been on aspirin chronically since birth. Clinical
assessment of parents showed no cardiac alterations.
Patient 3 was ﬁrst seen as a 25-week fetus, for bradycardia.
As AV block was suspected, the mother was started on
Figure 1 Electrocardiogram of patient 2 at birth, showing irregular rhythm with no P or F waves and a QT interval of 290 msec.
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pregnancy. Maternal autoimmune screening was negative.
A female baby was born with uncomplicated elective caesar-
ean section, Apgar 7 and 9. After birth the ECG showed AF
with junctional scape rhythm around 80 bpm, QTc interval
290 ms. Echocardiography was normal. At day of life 14, an
electrophysiology study was performed using an esophagealFigure 2 Electrocardiogram of patient 3 at 9 years of age, showing alead. Neither atrial nor ventricular pace capture was possible,
and intravenous adenosine had no effects. Multiple electric
cardioversions were attempted, with no success. Finally
aspirin and amiodarone were started. Two months later,
another electric cardioversion was performed and this success-
fully restored sinus rhythm. One month later, AF was again
noted, amiodarone was discontinued, and ﬂecainide wastrial ﬁbrillation, narrow QRS complexes, and short QTc interval.
Figure 3 Sequencing analysis displaying a de novo missense pathogenic
mutation (p.V141M) in exon 2 of the KCNQ1 gene that codiﬁes the
potassium channel KvLQT1. Change of G to A in the KCNQ1 gene
nucleotide 421 (c.421G4A), which carries a replacement of GTG valine
(V, Val) by ATG, methionine (M, Met), at position 141 (p.V141M,
p.Val141Met) of the transmembrane domain S1.
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later, with initial success, but eventually AF with rapid
ventricular response returned. The patient was weaned off
antiarrhythmic drugs. At age 4, the child remained in AF with
short QT interval. Echocardiography showed mild LV dilata-
tion (LV dimensions þ2 to þ2.5 z-score for body surface
area). At last follow-up, at age 9, she remains in AF and short
QT interval (Figure 2). Echocardiography shows mild LV
dilatation (LV dimensions þ2 to þ2.5 z-score for body
surface area) with severe aortic root dilatation (z score
þ4.02). So far, no pacemaker has been placed in this girl,
as she remains asymptomatic, though considering the aortic
root dilatation, a pacemaker is being considered. Clinical
assessment of parents showed no cardiac alterations.Genetic analysis
The genetic analysis revealed the same missense p.V141M
pathogenic mutation in all 3 samples. This pathogenic
mutation, which induces a substitution of G to A at
nucleotide 421, c.421G4A (GTG to ATG) and a substitu-
tion of valine (Val, V) to methionine (Met, M) at position
141 (Figure 3), was already described.27 Sequence analysisFigure 4 Multiple sequence alignment and taxonomy. Conservation of the altere
position of conserved amino acid between species.of the biological parents’ DNA of each baby failed to
identify the mutation, indicating that p.V141M_KCNQ1
represents a de novo pathogenic mutation in all 3 infants.
The p.V141M_KCNQ1 genetic variation was described
as disease-associated in 2005.27 In order to update genetic
data, we consulted the current online databases. No report of
this variant in the control population was identiﬁed. In
addition, new current in silico analyses were used and they
all predicted a deleterious effect of the variation. Finally,
alignment between species showed a high conserved posi-
tion (Figure 4).Discussion
In 2005, Hong et al27 identiﬁed a missense mutation
(p.V141M) in the KCNQ1 gene, which causes AF and
shortens the QT interval by altering the gating of IKs
channels—to our knowledge, the only pathogenic mutation
associated with this rare entity, so far. In 2008, Restier et al29
described that p.V141 causes AF and SQTS, mainly owing
to the markedly slow IKs deactivation, such that a proportion
of the channels remain in the open state. Recently, Chan
et al30 provided AF mechanisms for understanding the
effects on channel deactivation underlying the mutation.
The constitutive activation is predicted to markedly shorten
action potential duration in the atria and ventricles, display-
ing V141M KCNQ1-KCNE1 heteromultimers and abnormal
gating, thereby predisposing to AF and short QT.
The identiﬁcation of similar clinical ﬁndings, previously
reported by Hong et al, in 2 more unrelated children who
carry the same de novo genetic alteration is an uncommon
genetic phenomenon. Thus, from the clinical point of view,
this syndrome is responsible for a very speciﬁc clinical
phenotype. In other clinical-genetic syndromes it has been
difﬁcult to link the different mutations to a possible
syndrome because of the broad distribution of mutations.
It is reasonable to expect that the p.V141M mutation would
also shorten atrial action potentials and cause AF in affected
children. All children presented in this report showed AF
with very poor AV conduction causing severe bradycardia
while in utero. When they were born, their heart rates were in
the 60–80 bpm range, much lower than the expected aver-
age heart rate of 140 bpm.31 In 2007, a knock-in p.
S140G_KCNQ1 mouse model was reported showing gain-
of-function that causes AV node dysfunction.32 However,d amino acid in the genetic variation p.V141M. The asterisk (*) indicates the
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function is still, at present, speculative.27
Furthermore, from the genetic point of view, the identi-
ﬁcation of the same de novo mutation in 3 unrelated children
suggests a highly probabe mutation-speciﬁc disease. The
pathogenic role of this variant is supported by in silico
predictions and conserved protein region between species.
In addition, the mutation is located in codon 141 and from
position I132 to A150, 11 more pathogenic mutations have
been described (https://portal.biobase-international.com/
hgmd/pro/allmut.php), suggesting that the domain S1
appears to be a crucial segment in the function of the protein.
The fact that 3 unrelated families showed the same de novo
mutation suggests that this protein domain could be more
predisposed to suffer alterations, possibly owing to the
ineffective DNA mismatch repair system. All these facts
suggest this site as a mutational hotspot. However, further
mechanistic studies should be performed to clarify this
exceptionally unusual genetic phenomenon.
Interestingly, all patients developed LV dilatation in
various severities from mild to severe dilated cardiomyop-
athy. The ﬁrst pathophysiological suspected mechanism was
pacemaker-induced cardiomyopathy. In fact, patient 1 devel-
oped dilatation while being paced in the RV, and when she
was switched to LV stimulation she had a slight improve-
ment. But, contrary to what happens in pacemaker-induced
cardiomyopathy, replacement of the stimulation site did not
signiﬁcantly improve her dilatation. In addition, patient 3
(not paced) presented with moderate dilatation of the LV.
Furthermore, patient 2 had a pacemaker and was brieﬂy
treated with quinidine. The role of quinidine in LV dilatation
is certainly unknown and the sample size is not sufﬁcient to
perform statistical analysis. Thus, the role of this channel-
opathy in causing structural heart disease remains unclear
and a matter for future research.
Conclusions
We have described the clinical late follow-up of 3 unrelated
patients who presented with AF and bradycardia in utero,
associated with SQTS. All 3 carry the same de novo
pathogenic mutation, p.V141M_KCNQ1. We support the
highly pathogenic role of this mutation, associated with
development of ventricular dilatation and heart failure.
We recommend genetic analysis in patients with similar
clinical ﬁndings.
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